Compare TRVG & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | BNR |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | Germany | China |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.2M | 252.7M |
| IPO Year | 2015 | 2019 |
| Metric | TRVG | BNR |
|---|---|---|
| Price | $2.67 | $19.60 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.09 | N/A |
| AVG Volume (30 Days) | 26.7K | ★ 29.3K |
| Earning Date | 05-05-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.59 | $111.65 |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.59 | $2.18 |
| 52 Week High | $5.83 | $41.72 |
| Indicator | TRVG | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 46.03 | 54.86 |
| Support Level | N/A | $19.72 |
| Resistance Level | $3.22 | $23.42 |
| Average True Range (ATR) | 0.12 | 1.33 |
| MACD | -0.01 | 0.72 |
| Stochastic Oscillator | 37.84 | 95.53 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.